Cipher Pharmaceuticals Inc.

Total Valuation

Cipher Pharmaceuticals Inc. carries a market capitalization of 244.52M, placing it among publicly traded companies globally. Its enterprise value stands at 285.29M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Cipher Pharmaceuticals Inc. currently has 25.39M shares outstanding.

Valuation Ratios

Cipher Pharmaceuticals Inc. trades at a trailing price-to-earnings ratio of 10.13. The price-to-sales ratio is 5.92, and the price-to-book ratio stands at 2.14.

Enterprise Valuation

On an enterprise value basis, Cipher Pharmaceuticals Inc. trades at an EV/EBITDA multiple of 10.60 and an EV/FCF ratio of 10.16. The EV/Sales ratio of 5.75 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 14.46 provides insight into valuation relative to core operating earnings.

Financial Position

Cipher Pharmaceuticals Inc. maintains a current ratio of 1.59, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.27, indicating conservative leverage, while an interest coverage ratio of 527.92 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Cipher Pharmaceuticals Inc.'s stock has declined approximately -13.63229% over the past 52 weeks. The 50-day moving average sits at 10.73, while the 200-day moving average is 11.55.

Income Statement

Over the trailing twelve months, Cipher Pharmaceuticals Inc. generated 49.62M in revenue and converted that into 28.99M in net income, yielding earnings per share of 1.12. EBITDA reached 26.92M, while operating income came in at 19.73M.

Balance Sheet

Cipher Pharmaceuticals Inc. holds 9.11M in cash and equivalents against 367,000.00 in total debt, resulting in a net debt position of -9.11M. Total book value stands at 137.25M, with working capital of 11.47M providing operational flexibility.

Cash Flow

Cipher Pharmaceuticals Inc. produced 27.06M in operating cash flow over the past twelve months. After subtracting -934,000.00 in capital expenditures, free cash flow totaled 26.12M - equivalent to 1.03 per share.

Margins

Cipher Pharmaceuticals Inc. operates with a gross margin of 81.40, reflecting its pricing power and cost economics. The operating margin of 39.76 and net profit margin of 58.42 provide insight into operational efficiency.

Dividends & Yields

Scores

Cipher Pharmaceuticals Inc. posts an Altman Z-Score of 13.02, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.